Lv5
960 积分 2024-08-01 加入
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial
2天前
已完结
Acetylcholine receptor antibody and clinical response to thymectomy in myasthenia gravis
2天前
已关闭
Intravenous Efgartigimod or Intravenous Immunoglobulin in Guillain‐Barre Syndrome: An Observational Multicenter Study
7天前
已完结
Evaluation of the post-marketing safety of eculizumab from 2007 to 2025: A real-world pharmacovigilance study and signal analysis based on the FAERS database
9天前
已完结
Are monoclonals the only panacea for treatment of aquaporin-4 positive NMOSD? Experience from a low-&middle-income (LMIC) region
10天前
已完结
Opposing effects of efgartigimod and rozanolixizumab on serum albumin levels in patients with generalized myasthenia gravis
11天前
已完结
Immunosuppressive therapy in elderly patients with neuromyelitis optica spectrum disorder: a retrospective multicentre study
16天前
已完结
Moving beyond immunoglobulin therapy for CIDP with efgartigimod
18天前
已完结
Navigating the switch from IVIG to FcRn inhibition in CIDP: Clinical insights
18天前
已完结
Early differential diagnosis between acute inflammatory demyelinating polyneuropathy and acute-onset chronic inflammatory demyelinating polyneuropathy in children: Clinical factors and routine biomarkers
18天前
已完结
皖公网安备34019202002308
